Togo Launches New Malaria Vaccine to Safeguard 269,000 Children Against the Disease

Togo Launches Nationwide Malaria Vaccination Campaign With New R21 Vaccine

September 4, 2025

Lomé, Togo – A significant public health initiative commenced in Togo on September 1, 2025, as the nation began administering the R21/Matrix-M malaria vaccine as part of its routine immunization schedule. The ambitious program aims to shield approximately 269,000 children across all 39 of the country’s health districts from the devastating effects of malaria.

the introduction of this vaccine marks a pivotal moment in togo’s sustained fight against malaria, a disease that disproportionately affects young children. Minister of Health and Public hygiene, Tchin Darré, emphasized the government’s commitment to eradicating the disease, stating that this vaccination drive is crucial to enabling communities to fully contribute to national growth by 2030, as reported by the World Health Organization (WHO).

A Collaborative Effort

This expansive vaccination campaign is the result of strong collaboration between the Togolese government, the WHO, UNICEF, Gavi, the Vaccine Alliance, and several other key technical and financial partners. Their combined resources and expertise are instrumental in ensuring the successful implementation of this essential public health measure.

The Burden of Malaria in Togo

Malaria remains a persistent health threat across all regions of Togo, with cases peaking during the rainy season when mosquito populations flourish. Recent data from 2022 reveals the demographic most heavily impacted: children under the age of five accounted for 64% of confirmed malaria cases, representing 32% of all outpatient consultations and a staggering 53% of hospitalizations. Tragically,hospital mortality among this age group reached 65%,underscoring the urgent need for preventative measures like this new vaccine.

The government of Togo has already allocated a considerable $271.7 million to its National Malaria Control Plan, demonstrating a strong commitment to tackling the disease. By adding the R21/Matrix-M vaccine to its national immunization program, Togo now stands as the 22nd african country to adopt this innovative preventative measure.

Key Statistic	data (2022)
Malaria Cases (Under 5s)	64% of confirmed cases
Outpatient Consultations (Malaria)	32% of total consultations
Hospitalizations (Malaria)	53% of total hospitalizations
Hospital Mortality (Under 5s)	65% of malaria deaths

Did You know? The R21/Matrix-M vaccine has shown promising results in clinical trials, demonstrating high efficacy in preventing malaria in children.

Pro Tip: Staying informed about malaria prevention methods – such as using mosquito nets and repellents – in addition to vaccination, is your best defense against this preventable disease.

What impact do you foresee this vaccination campaign having on Togo’s healthcare system? How can international collaboration further accelerate malaria eradication efforts globally?

Understanding the R21/Matrix-M Vaccine

The R21/Matrix-M vaccine is a novel malaria vaccine developed by the University of Oxford and manufactured by the Serum Institute of India. It utilizes a modified protein from the malaria parasite combined with a potent adjuvant, Matrix-M, to stimulate a robust immune response. recent large-scale trials have indicated an efficacy of up to 77% over 12 months, offering significant protection against clinical malaria.The WHO has recommended this vaccine for widespread use in children living in areas with moderate to high malaria transmission, as reported in the World Health Organization’s official statement.

Frequently Asked Questions About the R21 Vaccine

• What is the R21 vaccine? The R21/matrix-M vaccine is a new malaria vaccine designed to prevent illness in children.
• How effective is the R21 vaccine? Clinical trials have shown the R21 vaccine to be up to 77% effective in preventing malaria over 12 months.
• Who is eligible for the R21 vaccine in Togo? The initial phase targets approximately 269,000 children across all 39 health districts.
• Is the R21 vaccine safe? The R21 vaccine has undergone rigorous testing and has been deemed safe by the WHO and regulatory authorities.
• How does the R21 vaccine work? It uses a modified malaria protein and an adjuvant to stimulate the immune system to fight the parasite.
• What other malaria prevention methods are recommended? Using insecticide-treated bed nets, repellents, and prompt treatment of malaria cases remain key prevention strategies.

Share this article and help raise awareness about the fight against malaria!

What is the target population for the malaria vaccination campaign in Togo?

Understanding the Impact of Malaria in Togo & West Africa

Togo has recently initiated a nationwide vaccination campaign utilizing a new malaria vaccine, aiming to protect approximately 269,000 children under the age of three. this initiative is notably crucial given the significant burden of malaria in Togo and across West Africa. Malaria remains a leading cause of childhood illness and death in the region, disproportionately affecting vulnerable populations. The World Health Association (WHO) estimates that in 2022, there were 249 million malaria cases globally, resulting in 625,000 deaths, with the African continent accounting for the vast majority.

The New Malaria Vaccine: A Game Changer?

The vaccine being deployed in Togo is a newer generation malaria vaccine,building on the success of the RTS,S/AS01 vaccine (Mosquirix) which has been piloted in Ghana,Kenya,and Malawi. While Mosquirix demonstrated significant efficacy, this new vaccine offers potential advantages, including possibly higher efficacy and a different mechanism of action. Details regarding the specific vaccine type are still emerging, but the core goal remains the same: to reduce the incidence of severe malaria and associated mortality in young children.

Target Population: Children under 3 years old are the primary focus due to their heightened vulnerability to severe malaria complications.

Vaccination Schedule: The vaccination schedule typically involves multiple doses administered over several months to build sufficient immunity. Specific schedules will be determined by Togolese health authorities.

Delivery Mechanism: The campaign utilizes a combination of fixed health facilities and outreach programs to ensure widespread access, even in remote areas.

Malaria Parasite Species in Africa & Ethiopia

Understanding the specific Plasmodium species prevalent in a region is vital for effective malaria control. The WHO reports that five parasite species cause malaria in humans,with plasmodium falciparum and Plasmodium vivax posing the greatest public health threat.Both of these species are found in Ethiopia, and their prevalence varies across different regions of Africa. Knowing the dominant species informs treatment protocols and vaccine advancement strategies.

Benefits of Malaria Vaccination Programs

Implementing a malaria vaccine program like the one in Togo offers a multitude of benefits:

Reduced Child Mortality: The most significant benefit is a decrease in deaths caused by severe malaria, particularly among infants and young children.

Decreased Healthcare Burden: Fewer malaria cases translate to reduced strain on healthcare systems, freeing up resources for other health priorities.

Improved Economic Productivity: Healthy children are more likely to attend school and contribute to the workforce later in life, boosting economic productivity.

Reduced Anemia Prevalence: Malaria frequently enough causes severe anemia, especially in children. Vaccination can help mitigate this effect.

Strengthened Health Systems: Large-scale vaccination campaigns require robust health infrastructure and trained personnel, leading to overall improvements in healthcare delivery.

Challenges to Malaria Vaccine Rollout

Despite the promise of malaria vaccines, several challenges need to be addressed for successful implementation:

Vaccine Supply & Cost: Ensuring a consistent and affordable supply of the vaccine is crucial, particularly for low-income countries.

Cold Chain Management: Maintaining the vaccine’s efficacy requires a reliable cold chain infrastructure to ensure it remains at the correct temperature during storage and transportation.

Community Acceptance & Education: Addressing vaccine hesitancy and educating communities about the benefits of vaccination are essential for achieving high coverage rates.

Integration with Existing Interventions: Vaccination should be integrated with other proven malaria control measures, such as insecticide-treated bed nets (ITNs), indoor residual spraying (IRS), and prompt diagnostic testing and treatment.

Monitoring & Evaluation: Continuous monitoring and evaluation are needed to assess the vaccine’s impact and identify areas for enhancement.

Togo’s Commitment to Malaria Control

Togo has demonstrated a strong commitment to combating malaria through various initiatives, including:

Mass Distribution of ITNs: Regular distribution campaigns ensure that households have access to insecticide-treated bed nets, a key preventative measure.

Seasonal Malaria Chemoprevention (SMC): Administering antimalarial drugs to children during the peak transmission season helps prevent illness.

Improved Diagnostics & Treatment: Expanding access to rapid diagnostic tests (RDTs) and effective antimalarial drugs ensures prompt and appropriate treatment.

Vector Control Programs: Targeted interventions to control mosquito populations, such as IRS, are implemented in high-transmission areas.

The Future of Malaria Prevention

The launch of this new malaria vaccine in Togo represents a significant step forward in the fight against this deadly disease. Continued research and development are crucial for creating even more effective vaccines and innovative control strategies. Combining vaccination with existing interventions, strengthening health systems, and fostering international collaboration will be essential for achieving the global goal of malaria eradication.

Keywords: Malaria, Malaria Vaccine, Togo, West Africa, Plasmodium falciparum, Plasmodium vivax*, Childhood Illness, Disease Prevention, Public health, Vaccination Campaign, RTS,S/AS01,